Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitomycin C with or without locoregional hyperthermia for intermediate-risk non-muscle-invasive bladder cancer
NL-OMON39804Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mitomycin c in bladder cancer, transitional cell carcinoma of the bladder (TCC) and non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Recurrence rate and Recurrence-free survival. Started Sep 2015; status: recruiting.
02
Drugs
mitomycin c
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NL-OMON39804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39804.